US News

Biohaven's stock jumps 12% after saying its migraine drug had $93 million in sales in Q2

Jump To The Original Source

Facebook Comments

Check Also

Working from home home can reduce migraine intensity, research shows

Published by DPA Working from home can help ...

Archives